Quantcast
Last updated on April 17, 2014 at 7:47 EDT

Latest Cathepsin Stories

2011-11-14 15:15:00

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain. Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity...

2011-11-03 05:00:00

MENLO PARK, Calif., Nov. 3, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, today announced the appointment of David B. Karpf, M.D. as chief medical officer. Dr. Karpf has more than 20 years of experience in guiding the clinical development of novel therapeutics, both at growing biotechnology firms and within large...

2011-05-31 21:15:59

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of ÃŽ²-amyloid (AÃŽ²) in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit. A paper detailing the findings has been published as an...

2010-06-02 13:30:33

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis "“ cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography. "This assay is important because researchers and pharmaceutical companies need a dependable method for sensitively detecting a small...

2010-01-17 08:25:00

In the February 1st issue of G&D, Dr. Johanna Joyce and colleagues at Memorial Sloan Kettering Cancer Center lend new insight into the mechanism by which tumor-associated macrophages promote malignant progression. The paper will be made available online ahead of print at www.genesdev.org. Innate immune cells, including macrophages, comprise a large fraction of the cellular environment that infiltrates tumors "“ the so-called "tumor microenvironment". Tumors have a dynamic...

2009-11-12 07:00:00

ORLANDO, Fla., Nov. 12 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis. The...

2009-09-22 10:04:02

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have uncovered what happens to biomimetic nanoparticles when they enter human cells. They found that the important proteins that make up the outer layer of these nanoparticles are degraded by an enzyme called cathepsin L. Scientists now have to take this phenomenon into account and overcome this process to ensure the exciting field of nanomedicine can progress. The research is published today (September...

49914ccb21aae7e5eb97eea1b22d3867
2005-08-01 18:44:00

(Philadelphia, PA) - Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time. This study also demonstrates a new mechanism for how viral proteins are activated within host cells, states senior author Paul Bates, PhD, an Associate Professor in the...

2005-06-24 15:00:00

June 23, 2005 "” Scientists have found a new role for a previously identified enzyme that may make it a target for anti-inflammatory treatments. The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to...